What treatment options remain for patients with advanced hepatocellular carcinoma (HCC) whose disease progresses following targeted therapy combined with immunotherapy? At the 2026 European Society for Medical Oncology (ESMO) Congress, a retrospective study reported preliminary results of aipaluolitovorelizumab (hereafter referred to as the "combination antibody regimen") combined with arterial interventional therapy and bevacizumab. The study included 13 patients, with objective response rates (ORRs) of 38.46% and 46.15% according to RECIST 1.1 and mRECIST, respectively. Oncology Frontier interviewed Professor Tianqi Zhang of Sun Yat-sen University Cancer Center to discuss the treatment design, management of intrahepatic lesions, and future research directions.

Exploring New Later-Line Treatment Options: Interventional Therapy Combined with Systemic Treatment After Progression on Targeted Therapy and Immunotherapy

Oncology Frontier:

What is the research value of this triple-combination regimen for patients whose disease progresses after targeted therapy combined with immunotherapy?

Professor Tianqi Zhang: There are an increasing number of first-line treatment options for advanced HCC. However, what to do when patients experience disease progression after targeted therapy combined with immunotherapy remains a common clinical challenge. Some exploratory studies have investigated rechallenge with single-agent or dual-agent immunotherapy, but further evidence is still needed to guide later-line treatment for this patient population.

For many patients, intrahepatic lesions remain difficult to manage after disease progression. As an interventional radiologist, I believe that, following comprehensive assessment, arterial interventional therapy can be used at different stages of treatment to selectively and precisely embolize or perfuse intrahepatic lesions. The aim is to control tumor burden while preserving liver function as much as possible, thereby creating room for concurrent systemic treatment. Interventional therapy may promote the release of tumor antigens and enhance antitumor immune responses, but these mechanisms still need to be confirmed through basic and translational research.

This study retrospectively reviewed 13 patients who received combined treatment with arterial interventional therapy, the combination antibody regimen, and bevacizumab. The ORR was 38.46% according to RECIST 1.1 and 46.15% according to mRECIST, with two patients achieving complete responses. However, because this was a small study without a control group, further evidence from ongoing prospective studies is needed to support this combination treatment strategy.

Dual-Checkpoint Immunotherapy Combined with Local Treatment: Exploring Synergy Across Multiple Mechanisms

Oncology Frontier:

What is the scientific rationale for combining dual-checkpoint immunotherapy with interventional therapy and anti-angiogenic treatment?

Professor Tianqi Zhang: The mechanisms underlying disease progression after immunotherapy are complex. Simply switching to another drug targeting the same molecule or pathway may not necessarily produce satisfactory efficacy. The combination antibody regimen modulates immune responses through two pathways, PD-1 and CTLA-4. PD-1 and CTLA-4 act at different stages of the immune response, and their combined blockade offers a strategy worth investigating and potentially applicable to patients whose disease progresses after immunotherapy.

Within this combination, arterial interventional therapy primarily targets intrahepatic lesions, bevacizumab acts on the VEGF pathway, and dual-checkpoint immunotherapy aims to modulate antitumor immune responses. The treatment strategy is designed to connect intrahepatic disease control with systemic therapy. Whether antigen release following interventional treatment, changes in the tumor microenvironment, and immune modulation can produce synergistic effects still requires validation through mechanistic studies and prospective clinical trials.

For individual patients, the choice of treatment strategy must continue to take into account liver function, recurrent tumor characteristics, previous treatment regimens, and adverse events.

Preserving Liver Function: Comprehensive Management Throughout Combination Treatment

Oncology Frontier:

When administering combination treatment, how can clinicians balance tumor control with patient tolerability?

Professor Tianqi Zhang: Liver functional reserve is an important factor when developing later-line treatment strategies for HCC. Following first-line treatment, underlying liver disease, tumor burden, and previous therapies may all affect liver function. Before deciding whether to proceed with combination treatment, we need to comprehensively assess liver function, performance status, lesion distribution, and previous treatment history to determine whether the patient remains eligible for both interventional and systemic therapies.

For patients receiving interventional treatment in later lines, more meticulous procedures are required. When selecting the embolization or perfusion approach and determining treatment timing, we must consider both lesion control and preservation of liver function. This is not simply a matter of reducing treatment intensity. Rather, the scope and extent of treatment should be determined according to hepatic reserve and tumor characteristics, followed by close monitoring after the procedure.

Among the 13 patients reported in this retrospective analysis, the incidence of grade ≥3 adverse events was 38.46%, and no grade 5 adverse events were observed. Grade 3 neutropenia occurred in 30.77% of patients, and one case of grade 4 AST elevation was also reported. Given the small sample size, these observations are not yet sufficient to fully characterize the risks associated with this combination regimen.

During treatment, complete blood counts and liver function should be monitored. When abnormalities occur, clinicians need to consider possible causes comprehensively, including reactions following interventional treatment, underlying liver disease, tumor progression, and immune-related liver injury.

Treatment after resistance to targeted therapy combined with immunotherapy requires multidisciplinary collaboration. Interventional radiology, hepatobiliary surgery, medical oncology, and imaging teams should jointly assess treatment strategies based on each patient’s condition. When anti-angiogenic agents are used, clinicians should also pay attention to blood pressure, proteinuria, and bleeding risk, while monitoring for immune-related adverse events. A treatment regimen can only be implemented when the patient is able to tolerate it and liver function permits.

Building Evidence and Exploring Later-Line Treatment Pathways

For patients with advanced HCC whose disease progresses after targeted therapy combined with immunotherapy, subsequent treatment must address not only tumor control but also practical challenges such as declining hepatic reserve and limited treatment tolerability. This study combined arterial interventional therapy with dual-checkpoint immunotherapy and anti-angiogenic treatment, providing a new research approach for patients whose disease progresses after immunotherapy.

The study observed preliminary signals of tumor response. However, the current findings are based on a small retrospective analysis. Prospective studies with larger patient populations are needed to validate efficacy and safety, while exploring potentially responsive populations according to factors such as liver function, tumor burden, previous treatment, and sites of disease progression.

From a clinical perspective, future evaluations should also focus on the timing and extent of interventional treatment, its impact on liver function when combined with systemic therapy, and whether patients can tolerate and continue treatment. As further research and follow-up data accumulate, we hope to gain clearer answers about which patients are most suitable for this treatment approach and what benefits it may provide, ultimately establishing a more reliable evidence base for patients with advanced HCC resistant to targeted therapy combined with immunotherapy.

Professor Tianqi Zhang